ArticleJournal of cancer research and clinical oncology2025

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.

Satoshi Endo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.